

# Genova, 27<sup>th</sup>-28<sup>th</sup> September 2016





#### FACULTY

Tadej Avcin (Lubljana, Slovenia) Fabrizio De Benedetti (Rome, Italy) Marco Gattorno (Genova, Italy) Michael Hofer (Lausanne, Switzerland) Berent Prakken (Utrecht, The Netherlands) Angelo Ravelli (Genova, Italy) Johannes Roth (Muenster, Germany) Lucy Wedderburn (London, UK) Nico Wulffraat (Utrecht, The Netherlands) Rolando Cimaz (Firenze, Italy) Carine Wouters (Leuven, Belgium)

#### JUNIOR FACULTY

Felicitas Bellutti-Enders (Lausanne, Switzerland) Alexandre Belot (Lyon, France) Alessandro Consolaro (Genova, Italy) Silvia Federici (Genova, Italy) Dirk Holzinger (Muenster, Germany) Clara Malattia (Genova, Italy) Eve Smith (Liverpool, UK) Joost Swart (Utrecht, The Netherlands) Bas Vasert (Utrecht, The Netherlands)

#### LOCAL ORGANISING COMMITTEE

Alessandro Consolaro (Genova, Italy) Roberta Caorsi (Genova, Italy) Gabriella Giancane (Genova, Italy) Pieter van Dijkhuizen (Genova, Italy) Eve Smith (Liverpool, UK) Maria Tsinti (Athens, Greece)

#### LOCAL ORGANISING SECRETARIAT

Isituto Giannina Gaslini Simona Angioloni Chiara Pallotti Centro Italiano Studi e Formazione "Germana Gaslini" (CISEF) Caterina Cogorno Claudia Olcese

### **GENERAL INFORMATION**

YIM MEETING – DATES AND LOCATION September 27<sup>th</sup>-28<sup>th</sup>

Badia Benedettina della Castagna

Genova – Quarto dei Mille

#### CONTACTS

Simona Angioloni Dipartimento di Scienze Pediatriche Generali e Specialistiche U.O.C. Pediatria II - Reumatologia IRCCS Istituto Giannina Gaslini Via Gerolamo Gaslini 5, 16147 Genova Paediatric Rheumatology INternational Trials Organisation (PRINTO) Tel.: 0039-010-393425 Fax.: 0039-010-4211018 Email: <u>SimonaAngioloni@gaslini.org</u>

Alessandro Consolaro, MD, PhD Pediatria II-Reumatologia, Istituto G. Gaslini EULAR Centre of Excellence in Rheumatology 2008-2018 Largo G. Gaslini, 5 16147 Genova, Italy Tel.: +39 010 56362729 Fax: +39-010-5636211 or +39-010-393324 E-mail: alessandroconsolaro@gaslini.org

Caterina Cogorno CISEF GASLINI | Centro Internazionale di Studi e Formazione Germana Gaslini Villa Quartara, via Romana della Castagna, 11A - 16148 Genova - Italia Telefono:+39 010 56362 855 | Fax:+39 010 5636 2885 e-mail: caterinacogorno@cisef.org

## SCIENTIFIC INFORMATION

#### **POSTER TRAILERS:**

No paper posters this year! Each accepted poster will be presented in 3 slides. Poster tours will be held in 5 stations, with a laptop and a projector. Presenters will have 3 minutes to talk and 2 minutes for questions. Please, avoid background/introduction slides and instead concentrate on your hypothesis and key results. We will try to group the posters according to the topic. Each slide should display the name of the presenter, centre and title of the work. During the congress, participants will have online access to the abstracts and, if previous authorization is given by the presenting author, the poster trailers.

#### **ORAL PRESENTATIONS:**

There will be 4 sessions for oral presentations. Each presentation will be allocated 10 minutes for the talk and 2 minutes for the discussion

#### LUNCH WITH THE PROFESSOR

Each lunch table will be assigned to a faculty member with a specific area of interest (e.g. JIA, SLE, JDM, Periodic Fevers, Scleroderma etc). YIs who want to network with the faculty member and other YI's interested in the same area as them will have to register via web in advance.

#### **YIM ABSTRACT AWARDS**

YIM attendees will vote for the two best clinical and basic science presentations. These will be awarded during the final lunch

## SCIENTIFIC PROGRAMME

#### Badia Benedettina della Castagna

#### 27<sup>th</sup> September 2016

# 12.00 -14.00 REGISTRATION, POSTERS UPLOAD AND REGISTRATION FOR THE FOLLOWING DAY NETWORKING LUNCH

#### Scientific Programme Summary

#### 27<sup>th</sup> September 2016

14.00 - 14.10	YIM Opening
14.10 - 14.30	Opening lecture: 15 years YIM: Looking back to the future – Prof. Berent Prakken
14.30 - 16.00	SESSION 1: 7 YI oral presentations
16.00 - 16.15	Young Investigators of the CARRA network – Jay Metha and Kristen Hayward
16.15 – 17.15	COFFEE BREAK AND POSTER TRAILERS
17.15 – 18.45	SESSION 2: 7 YI oral presentations
18.45 - 19.00	Revised Pediatric Rheumatology Syllabus – Prof. Tadej Avčin

#### Networking dinner: SYS Beach Club, Corso Italia, Genova

#### 28<sup>th</sup> September 2016

9.00 - 10.30	SESSION 3: 7 YI oral presentations
10.30 - 11.30	COFFEE BREAK AND POSTER TRAILERS
11.30 - 11.45	Overview of EMUNET – Anna Molto
11.45 - 13.15	SESSION 4: 7 YI oral presentations
13.15 – 14.15	LUNCH WITH THE PROFESSOR (REGISTRATION NEEDED) AND VOTING
14.15 - 14.30	CLOSING REMARKS AND AWARDS

## Scientific Programme

# 27<sup>th</sup> September 2016

14.00 - 14.10	YIM Opening		
14.10 - 14.30	Opening lecture: 15 years YIM: Looking back to the future – Prof. Berent Prakken		
14.30 - 16.00	SESSION 1: Oral presentations		
	Chairs: Marco Gattorno and Eve Smith		
	TYPE I INTERFERONOPATHIES: DIAGNOSTIC APPROACH AND PRELIMINARY RESULTS OF TREATMENT WITH A JAK1/2 INHIBITOR	Stefano Volpi	
	ADULT OUTCOMES IN A LARGE COHORT OF CHILDHOOD-ONSET SLE PATIENTS: CLINICAL OUTCOME AND QUALITY OF LIFE - THE CHILL-NL STUDY	Noortje Groot	
	MONOCYTES PROTEOMIC PROFILE OF PATIENTS WITH DIFFERENT AUTOINFLAMMATORY DISEASES: AN APPROACH TO IDENTIFY NEW BIOMARKERS	Federica Penco	
	MAGNETIC RESONANCE AND ECHOCARDIOGRAPHIC STRAIN RATE IMAGING FOR THE EARLY DETECTION OF CARDIAC INVOLVEMENT IN JUVENILE SYSTEMIC SCLEROSIS	Francesca Sperotto	
	PYRIN-ASSOCIATED AUTOINFLAMMATION WITH NEUTROPHILIC DERMATOSIS (PAAND): PRELIMINARY RESULTS OF A PROOF-OF- CONCEPT TRIAL WITH ANAKINRA	Lien Van Eyck	
	WHOLE EXOME SEQUENCING IN EARLY ONSET SYSTEMIC LUPUS ERYTHEMATOSUS	Ezgi Deniz Batu	
	PREDICTORS OF RECOVERY FROM LUPUS NEPHRITIS IN CHILDREN	Eve Smith	
16.15 – 17.15	COFFEE BREAK AND POSTER TRAILERS		
	PT1: Autoinflammatory diseases-1. Chairs: Marco Gattorno and Nienke ter Haar		
	PT2: JIA treatment and outcome. Chairs: Angelo Ravelli and Dirk Holzinger		
	PT3: Juvenile dermatomyositis. Chairs: Lucy Wedderburn and Claudia Bracaglia		
	PT4: Systemic JIA. Chairs: Fabrizio De Benedetti and Bas Vastert		
	PT5: Vasculitdes and scleroderma. Chair: Tadej Avčin and Francesca	a Sperotto	
17.15 – 18.45	SESSION 2: Oral presentations		
	Chairs: Nico Wulffraat and Dirk Holzinger		
	NATIONAL PROSPECTIVE ONLINE REGISTRY FOR JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED UVEITIS IN SPAIN	Juan M M Angarita	
	IS CONTRAST NECESSARY TO DETECT SACROILIITIS ON MRI IN JUVENILE SPONDYLOARTHRITIS ?	Nele Herregods	
	USEFULNESS OF ULTRASOUND JOINT SCORE IN THE ASSESSMENT OF CLINICAL ACTIVITY IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS	Estefania Quesada- Masachs	
	CHANGES IN SWITCHED MEMORY B CELLS ARE ASSOCIATED TO THE THERAPEUTIC RESPONSE TO TNF INHIBITION IN JIA	Emiliano Marasco	
	AN ACTIVE PRONGF-P75NTR AXIS PLAYS A PRO-INFLAMMATORY ROLE IN CHRONIC ARTHRITIS	Gaetana Minnone	

	DIFFERENCES IN DISEASE PHENOTYPE, MANAGEMENT AND	Alessandro
	OUTCOMES OF CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS	Consolaro
	THROUGHOUT THE WORLD – ANALYSIS OF 8,325 PATIENTS	
	ENROLLED IN THE EPOCA STUDY	
	SAFETY AND EFFICACY OF INFLIXIMAB AND ADALIMUMAB FOR	Vanessa Cecchin
	REFRACTORY UVEITIS IN JUVENILE IDIOPATHIC ARTHRITIS: TWO	
	YEAR FOLLOW UP DATA FROM THE ORCHIDEA REGISTRY	
18.30 - 18.45	Young Investigators of the CARRA network – Jay Metha and Kristen Hayward	

## Networking dinner: SYS Beach Club, Corso Italia, Genova

## 28th September 2016

9.00 - 10.30	0 SESSION 3: 7 YI oral presentations	
	Chairs: Johannes Roth and Bas Vastert	
	INFLAMMATORY GENE EXPRESSION PROFILE AND DEFECTIVE	Jessica
	INTERFERON-GAMMA AND GRANZYME K IN NATURAL KILLER	Vandenhaute
	CELLS OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS	
	PROTEOMIC DISCOVERY OF SJIA DIAGNOSTIC AND PHENOTYPIC BIOMARKERS	Faekah Gohar
	PHAGOCYTE INVOLVEMENT IN SYSTEMIC ONSET JUVENILE	Nienke ter Haar
	IDIOPATHIC ARTHRITIS	
	VALIDATION OF MRP8/14 SERUM LEVELS AS BIOMARKER FOR	Dirk Holzinger
	THE DIAGNOSIS OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN FEVER OF UNKNOWN ORIGIN	
	RECOMBINANT IL-1RA RESTORES THE IL-18-NK CELL AXIS IN	Wilco de Jager
	STEROID NAÏVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS	
	PATIENTS.	
	THE ABILITY OF TOCILIZUMAB INDUCES THE REMISSION IN	Mikhail M Kostik
	SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: THE MAIN	
	PREDICTORS	
	S100A8/A9 REGULATES IMMUNE RESPONSES IN DENDRITIC CELLS	David Popp
10.30 - 11.30	COFFEE BREAK AND POSTER TRAILERS	
	PT6: Autoinflammatory diseases-2. Chairs: Michael Hofer and Silvia	a Federici
	PT7: Imaging. Chairs: Clara Malattia and Pieter van Dijkhuizen	
	PT8: Around JIA. Chairs: Nico Wulffraat and Joost Swart	
	PT9: Predicting JIA outcome. Chairs: Johannes Roth and Alessandro Consolaro	
	PT10: SLE and miscellaneous. Chairs: Rolando Cimaz and Alexandre Belot	
11.30 - 11.45	Overview of EMUNET – Anna Molto	
11.45 - 13.15	SESSION 4: Oral presentations	
	Chairs: Angelo Ravelli and Felicitas Bellutti-Enders	
	A BAYESIAN MODEL FOR DISEASE ACTIVITY IN PATIENTS WITH	Pieter van
	JUVENILE DERMATOMYOSITIS	Dijkhuizen

	INFLAMMATORY MILIEU OF MUSCLE BIOPSIES AND CLINICAL	Erdal Sag
	FEATURES IN JUVENILE DERMATOMYOSITIS	
	NEUTRALIZATION OF INTERFERON-GAMMA IS EFFICACIOUS IN A	Giusi Prencipe
	MOUSE MODEL OF MACROPHAGE ACTIVATION SYNDROME	
	NEXT GENERATION SEQUENCING ANALYSIS OF FAMILIAL	Chiara Passarelli
	HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) RELATED	
	GENES IN MACROPHAGE ACTIVATION SYNDROME (MAS) AND	
	SECONDARY HLH (SECHLH)	
	EVALUATION PREDICTORS OF THE CUMULATIVE DOSE AND	Sirisucha
	DURATION OF CORTICOSTEROID AND METHOTREXATE	Soponkanaporn
	TREATMENT IN JUVENILE DERMATOMYOSITIS	
	GALECTIN-9, CXCL10 AND TNFRII, BIOMARKERS FOR DISEASE	Judith Wienke
	ACTIVITY IN JUVENILE DERMATOMYOSITIS, ARE MYOSITIS	
	SPECIFIC AND MAY REFLECT HIGHLY ACTIVATED ENDOTHELIUM	
	EVIDENCE BASED CRITERIA FOR CORTICOSTEROID	Gabriella Giancane
	TAPERING/DISCONTINUATION. AN ANALYSIS OF THE PRINTO	
	TRIAL IN NEW ONSET JUVENILE DERMATOMYOSITIS	
13.15 - 14.15	LUNCH WITH THE PROFESSOR (REGISTRATION NEEDED) AND VOTI	NG
14.15 – 14.30	CLOSING REMARKS AND AWARDS	

Autoinflamma	atory diseases -1 - Chairs: Marco Gattorno & Nienke	ter Haar
	BASELINE CHARACTERISTICS OF 116 PATIENTS WITH	
	CRONIC NON-BACTERIAL OSTEOMYELITIS (CNO)	
	INCLUDED IN A NATIONAL LONGITUDINAL COHORT	
PReS-ABS-1581	STUDY	Antonella Insalaco (Italy)
	CRYOPYRIN ASSOCIATED PERIODIC SYNDROMES (CAPS):	
	IMMUNOLOGICAL CHARACTERIZATION OF KNOCK-IN	
	MOUSE MODEL TO EXPLOIT NOVEL APPROACHES FOR	
PReS-ABS-1547	THE MODULATION OF THE NLRP3 INFLAMMASOME.	Arinna Bertoni (Italy)
	ASSOCIATION BETWEEN FAMILIAL MEDITERRANEAN	
	FEVER AND SPONDYLOARTHRITIS. CLINICAL	
	CHARACTERISTICS OF THE FRENCH CEREMAI PEDIATRIC	
PReS-ABS-1140	COHORT	Bilade Cherqaoui (France)
	HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF	
PReS-ABS-1501	CHILDREN WITH PFAPA SYNDROME	Claire Grimwood (France)
	DEFECT OF ADAPTIVE IMMUNITY IN ADA2 DEFICIENCY	
PReS-ABS-1465	PATIENTS	Francesca Schena (Italy)
11103 / 103 1103	AN UPDATE ON THE ITALIAN COHORT OF DADA2	
	PATIENTS AND AN ASSESSMENT OF A NOVEL	
PReS-ABS-1578	FUNCTIONAL SCREENING TEST	Roberta Caorsi (Italy)
TRE3-AD3-1370	RENAL AA AMYLOIDOSIS – A PIECE IN THE DIAGNOSTIC	
	PUZZLE OF CRYOPYRINOPATHY IN 10 FAMILY MEMBERS	Sarka Fingerhutova (Czech
PReS-ABS-1633	ACROSS 4 GENERATIONS	Republic)
FRE3-AD3-1033	NLRP3 INFLAMMASOME ACTIVITY IN MONOCYTES IS	(republic)
PReS-ABS-1491	REGULATED BY 12/15-LIPOXYGENASE.	Yvonne Kusche (Germany)
FRE3-AD3-1491	THE MULTIFACETED PRESENTATION OF CHRONIC	
	RECURRENT MULTIFOCAL OSTEOMYELITIS: A SERIES OF	
	466 CASES FROM THE EUROFEVER INTERNATIONAL	
PReS-ABS-1560	REGISTRY	Francesca Orlando (Italy)
PRES-ADS-1500	CLINICAL FEATURES DISTINGUISHING PATIENTS WITH	Francesca Onando (Italy)
	CHRONIC RECURRENT	
	MULTIFOCAL OSTEONYELITIS (CRMO) FROM PATIENTS	
PReS-ABS-1387	WITH TUMORAL OSTEOLYTIC LESIONS: A SINGLE CENTER	Martina Finatti (Italy)
PRES-ABS-1387	EXPERIENCE	Martina Finetti (Italy)
JIA treatment	and outcome - Chairs: Angelo Ravelli & Dirk Holzing	er
	MINIMAL CLINICALLY IMPORTANT DIFFERENCE OF THE	Benedetta Schiappapietra
PReS-ABS-1542	JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE	(Italy)
	TREATMENT AND 1-YEAR OUTCOMES OF AN INCEPTION	
PReS-ABS-1483	COHORT OF AUSTRALIAN CHILDREN WITH JIA.	Georgina Tiller (Australia)
	DEVELOPMENT AND INITIAL VALIDATION OF THE PARENT	Giedre Januskeviciute
PReS-ABS-1451	AND CHILD VERSIONS OF THE JADAS	(Lithuania)
	EFFECTIVENESS OF ETANERCEPT RELEASE SYSTEM WITH	Gokalp Basbozkurt
PReS-ABS-1215	MICROSPHERES IN RAT MODEL OF ARTHRITIS	(Turkey)

		1
	COST-EFFECTIVENESS OF FIRST YEAR TREATMENT FOR	
	JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN THE ERA OF	
PReS-ABS-1075	BIOSIMILARS	Maarit Tarkiainen (Finland)
	LONGTERM EXPERIENCE OF ABATACEPT THERAPY IN	O Kostareva (Russian
PReS-ABS-1622	JUVENILE IDIOPATHIC ARTHRITIS IN A SINGLE CENTER	Federation)
	DISEASE ACTIVITY STATES, REASONS FOR	
	DISCONTINUATION AND ADVERSE EVENTS IN 1038	
	ITALIAN CHILDREN WITH JUVENILE IDIOPATHIC	
PReS-ABS-1276	ARTHRITIS TREATED WITH ETANERCEPT	S. Verazza (Italy)
	USE OF GLUCOCORTICOIDS IN FIRST-LINE TREATMENT OF	
	JUVENILE IDIOPATHIC RHEUMATOID FACTOR NEGATIVE	
	POLYARTHRITIS: DATA FROM A GERMAN INCEPTION	
PReS-ABS-1543	COHORT	Tobias Schwarz (Germany)
	RELATIVE CONTRIBUTION OF THE FOUR COMPONENTS	
PReS-ABS-1518	OF THE JADAS10 IN DETERMINING THE TOTAL SCORE	Valentina Muratore (Italy)
	DMARD WITHDRAWAL IN JUVENILE IDIOPATHIC	
PReS-ABS-1559	ARTHRITIS PATIENTS IN CLINICAL REMISSION. A SINGLE	
	CENTER OBSERVATIONAL STUDY	Maria Tsinti (Greece)
luvenile derm	atomyositis - Chairs: Lucy Wedderburn & Claudia Bra	anglia
Juvenne derm	atomyositis - chairs: Lucy wedderburn & claudia Bra	lacagiid
	ANTI-SYNTHETASE AUTOANTIBODY IS SEEN IN PATIENTS	
	WITH OVERLAP MYOSITIS IN THE UK COHORT OF	Beverley Almeida (United
PReS-ABS-1171	PATIENTS WITH JVEUNILE DERMATOMYOSITIS	Kingdom)
	THE VASCULOPATHY OF JDM; EVIDENCE OF PERSISTENT	
	ENDOTHELIAL INJURY, HYPERCOAGULABILITY,	Charalampia
	SUBCLINICAL INFLAMMATION AND INCREASED ARTERIAL	Papadopoulou (United
PReS-ABS-1222	STIFFNESS.	Kingdom)
	COMPARISON OF THE PRINTO 2010 AND PRINTO/IMACS	
	2016 IMPROVEMENT CRITERIA IN THE PRINTO TRIAL IN	
PReS-ABS-1233	NEW ONSET JUVENILE DERMATOMYOSITIS	Claudio Lavarello (Italy)
	COMPARISON OF TREATMENT AND OUTCOME OF	
	CHILDREN WITH JUVENILE DERMATOMYOSITIS	
	FOLLOWED AT TWO EUROPEAN TERTIARY CARE	Giulia Camilla Varnier
PReS-ABS-1382	REFERRAL CENTERS	(Italy)
	PERIPHERAL BLOOD B CELLS ARE EXPANDED AND THEIR	
	CYTOKINE EXPRESSION IS DYSREGULATED IN JUVENILE	Meredyth Wilkinson
PReS-ABS-1002	DERMATOMYOSITIS	(United Kingdom)
	AUDIT OF INTRAVENOUS IMMUNOGLOBULIN	
	PROTOCOLS USED FOR THE TREATMENT OF JUVENILE	Qiong Wu (United
PReS-ABS-1008	DERMATOMYOSITIS	Qiong Wu (United Kingdom)
PReS-ABS-1008	DERMATOMYOSITIS EXPRESSION OF TYPE I AND TYPE II INTERFERONS IS	- ·
PReS-ABS-1008	DERMATOMYOSITIS EXPRESSION OF TYPE I AND TYPE II INTERFERONS IS INCREASED IN MUSCLE BIOPSIES OF JUVENILE	- ·
	DERMATOMYOSITISEXPRESSION OF TYPE I AND TYPE II INTERFERONS ISINCREASED IN MUSCLE BIOPSIES OF JUVENILEDERMATOMYOSITIS PATIENTS AND RELATED TO CLINICAL	Kingdom)
PReS-ABS-1008 PReS-ABS-1339	DERMATOMYOSITIS EXPRESSION OF TYPE I AND TYPE II INTERFERONS IS INCREASED IN MUSCLE BIOPSIES OF JUVENILE DERMATOMYOSITIS PATIENTS AND RELATED TO CLINICAL AND HISTOLOGICAL FEATURES	- ·
	DERMATOMYOSITISEXPRESSION OF TYPE I AND TYPE II INTERFERONS ISINCREASED IN MUSCLE BIOPSIES OF JUVENILEDERMATOMYOSITIS PATIENTS AND RELATED TO CLINICALAND HISTOLOGICAL FEATURESDEVELOPMENT AND VALIDATION OF A COMPOSITE	Kingdom)
PReS-ABS-1339	DERMATOMYOSITISEXPRESSION OF TYPE I AND TYPE II INTERFERONS ISINCREASED IN MUSCLE BIOPSIES OF JUVENILEDERMATOMYOSITIS PATIENTS AND RELATED TO CLINICALAND HISTOLOGICAL FEATURESDEVELOPMENT AND VALIDATION OF A COMPOSITEDISEASE ACTIVITY SCORE FOR JUVENILE	Kingdom) Rebecca Nicolai (Italy)
	DERMATOMYOSITISEXPRESSION OF TYPE I AND TYPE II INTERFERONS ISINCREASED IN MUSCLE BIOPSIES OF JUVENILEDERMATOMYOSITIS PATIENTS AND RELATED TO CLINICALAND HISTOLOGICAL FEATURESDEVELOPMENT AND VALIDATION OF A COMPOSITE	Kingdom)
PReS-ABS-1339	DERMATOMYOSITISEXPRESSION OF TYPE I AND TYPE II INTERFERONS ISINCREASED IN MUSCLE BIOPSIES OF JUVENILEDERMATOMYOSITIS PATIENTS AND RELATED TO CLINICALAND HISTOLOGICAL FEATURESDEVELOPMENT AND VALIDATION OF A COMPOSITEDISEASE ACTIVITY SCORE FOR JUVENILE	Kingdom) Rebecca Nicolai (Italy)
PReS-ABS-1339	DERMATOMYOSITISEXPRESSION OF TYPE I AND TYPE II INTERFERONS ISINCREASED IN MUSCLE BIOPSIES OF JUVENILEDERMATOMYOSITIS PATIENTS AND RELATED TO CLINICALAND HISTOLOGICAL FEATURESDEVELOPMENT AND VALIDATION OF A COMPOSITEDISEASE ACTIVITY SCORE FOR JUVENILEDERMATOMYOSITIS	Kingdom) Rebecca Nicolai (Italy)

	DERMATOMYOSITIS: CASE SERIES	
Systemic IIA	Chairs, Eabrizia da Banadatti 8. Pas Vastart	
Systemic JIA -	Chairs: Fabrizio de Benedetti & Bas Vastert	
	DISTINCT CHANGE PATTERNS OF LABORATORY	
	BIOMARKERS IN MACROPHAGE ACTIVATION SYNDROME	
	COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC	
	ARTHRITIS: A LATENT GROWTH MIXTURE MODEL	
PReS-ABS-1449	ANALYSIS	Alessandra Alongi (Italy)
	A NOVEL HOMOZYGOUS FRAMESHIFT MUTATION IN	
	LACC1 ASSOCIATED WITH SEVERE	Anne Thorwarth
PReS-ABS-1497	FAMILIAL FORMS OF JUVENILE IDIOPATHIC ARTHRITIS	(Germany)
	SERIAL SERUM INTERLEUKIN-6 LEVELS IN SYSTEMIC	
	JUVENILE IDIOPATHIC ARTHRITIS	Butsabong Lerkvaleekul
PReS-ABS-1486	AS A PREDICTOR OF TREATMENT RESPONSE	(Thailand)
	DYSBALANCED SERUM FACTOR ENVIRONMENTS CAN	
	DRIVE IL-17 OVER-EXPRESSION BY GAMMA DELTA T	Christoph Kessel
PReS-ABS-1485	CELLS IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS	(Germany)
	DEVELOPMENT AND INITIAL VALIDATION OF THE "MH	
	SCORE", A NEW DIAGNOSTIC TOOL THAT	
	DIFFERENTIATES PRIMARY HEMOPHAGOCYTIC	
	LYMPHOHISTIOCYTOSIS FROM MACROPHAGE	
PReS-ABS-1245	ACTIVATION SYNDROME	Francesca Minoia (Italy)
	INFLUENCE OF TOCILIZUMAB TREATMENT ON BONE	
	MINERAL DENSITY IN PATIENTS WITH SYSTEMIC	Rina Denisova (Russian
PReS-ABS-1168	JUVENILE IDIOPATHIC ARTHRITIS	Federation)
	CHANGE IN EXPERT CONSENSUS BASED ON AVAILABILITY	
	OF ADDITIONAL LABORATORY DATA OVER THE COURSE	
PReS-ABS-1288	OF MAS	Sergio Davì (Italy)
	TYPE I INTERFERON SCORE IN PERIPHERAL BLOOD OF	
PReS-ABS-1530	PATIENTS WITH PEDIATRIC RHEUMATIC DISEASES	Gian Marco Moneta (Italy)
	IMMUNE ABNORMALITIES LEADING TO EXAGGERATED	
	PRODUCTION OF IFN-GAMMA AND THE THERAPEUTIC	
	RESPONSE TO AN ANTI-IFNGAMMA ANTIBODY IN A	
PReS-ABS-1546	PATIENT WITH NLRC4 MEDIATED DISEASE	Claudia Bracaglia (Italy)
	INHIBITION OF INTERFERON PRODUCTION DRIVING	Marie-Louise Frémond
PReS-ABS-1362	TMEM173-ASSOCIATED AUTO-INFLAMMATION.	(France)
	·	
vasculitides a	nd scleroderma - Chairs: Tadej Avčin and Francesca	Sperotto
	THE AGE FEATURES OF KAWASAKI DISEASE, MOSCOW,	Alena Torbyak (Russian
PReS-ABS-1079	RUSSIAN FEDERATION.	Federation)
	EPIDEMIOLOGY OF KAWASAKI DISEASE IN ITALY:	
	SURVEILLANCE FROM NATIONAL HOSPITALIZATION	
PReS-ABS-1150	RECORDS	Angela Mauro (Italy)
	OPTIMAL ASPIRIN DOSE IN KAWASAKI DISEASE - THE	
PReS-ABS-1239	ONGOING BATTLE	Anita Dhanrajani (Canada)
	A SINGLE CENTRE EXPERIENCE OF PEDIATRIC SYSTEMIC	
PReS-ABS-1085	SCLEROSIS FROM NORTH INDIA	Ankur Kumar (India)
	RECURRENT ANGIOEDEMA IN A PATIENT WITH SYSTEMIC	
PReS-ABS-1557	LUPUS ERYTHEMATOSUS	Edi Paleka Bosak (Croatia)

	ASSESSMENT OF RELATIONSHIP BETWEEN IL-17 LEVELS	
	AND OXIDATIVE STRESS IN CHILDREN WITH	
PReS-ABS-1473	IMMUNOGLOBULIN A VASCULITIS	Hakan Kisaoglu (Turkey)
	T HELPER 17 (TH17) AND T REGULATORY (TREG) CELLS IN	
	CHILDREN WITH KAWASAKI DISEASE – EXPERIENCE FROM	
PReS-ABS-1159	A TERTIARY CARE CENTRE IN NORTH INDIA	Sagar Bhattad (India)
	TAKAYSU ARTERITIS IN CHILDREN: EXPERIENCE IN	Yulia Kostina (Russian
PReS-ABS-1077	OBSERVATION AND TREATMENT OF A SINGLE CENTER	Federation)

# Autoinflammatory diseases -2 - Chairs: Michael Hofer & Silvia Federici

	THE IMPACT OF GASTROINTESTINAL CLINICAL	
	MANIFESTATIONS IN AUTOINFLAMMATORY DISEASES	
	(AIDS): LESSONS FROM THE INTERNATIONAL EUROFEVER	
PReS-ABS-1209	REGISTRY	Alessia Omenetti (Italy)
	ANALYSES OF 247 PATIENTS WITH RECURRENT	Charlotte Eijkelboom
PReS-ABS-1237	INFLAMMATION OF UNKNOWN CAUSE	(Netherlands)
	RESULTS OF THE EUROFEVER DELPHI SURVEY FOR THE	Federica Vanoni
PReS-ABS-1083	CLASSIFICATION CRITERIA OF PFAPA SYNDROME	(Switzerland)
	THE PHENOTYPE AND GENOTYPE OF MEVALONATE	
	KINASE DEFICIENCY: A SERIES OF 114 CASES FROM THE	Jerold Jeyaratnam
PReS-ABS-1350	EUROFEVER REGISTRY	(Netherlands)
	DEVELOPMENT OF THE AUTOINFLAMMATORY DISEASE	
PReS-ABS-1174	DAMAGE INDEX (ADDI)	Kim Annink (Netherlands)
	CLINICAL RESPONSE TO USTEKINUMAB IN SEVERE	
	ERYTRODERMIC PSORIASIS CAUSED BY CARD-14	
PReS-ABS-1551	MUTATION (CARD-14 MEDIATED PSORIASIS; CAMPS)	Sara Signa (Italy)
	EVALUATION OF UNDIFFERENTIATED PERIODIC FEVER	
	WITH PRINTO-EUROFEVER CRITERIA AT BASELINE AND AT	
PReS-ABS-1264	FOLLOW-UP.	Silvia De Pauli (Italy)
	THE LONGITUDINAL EUROFEVER PROJECT: AN UPDATE	
PReS-ABS-1327	ON ENROLLMENT	Silvia Federici (Italy)
	RECOMMENDATIONS FOR GENETIC TESTING OF NLRP3	
	MUTATION-NEGATIVE CAPS PATIENTS THROUGH	Sonia Melo Gomes (United
PReS-ABS-1398	COMPARISON OF SEQUENCING METHODS	Kingdom)
	EFFECTIVE TREATMENT OF SEVERE JUVENILE PUSTULAR	
	PSORIASIS WITH CYCLOSPORINE AND ETANERCEPT: A	Chies Maria Stanbarger
PReS-ABS-1421	CASE REPORT UTILIZING AUTOINFLAMMATORY DISEASES	Chloe Maria Stephenson
	ACTIVITY INDEX (AIDAI) TO DOCUMENT TREATMENT	(Canada)
	RESPONSE	
Imaging - Chai	rs: Clara Malattia & Pieter von Dijkhuizen	
	INVENTION OF REHABILITATIVE GAMES USING THE LEAP	
	MOTION CONTROLLER FOR HAND REHABILITATION IN	
	CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND	
PReS-ABS-1587	INVESTIGATION OF ITS' EFFECTIVENESS	Ela Tarakci (Turkey)
	A NEW TOOL OF DISEASE ACTIVITY EVALUATION	
	THROUGH-OUT POWER DOPPLER ULTRASONOGRAPHY	
	AND SERUM VASCULAR MARKERS IN JUVENILE	Joanna Świdrowska-Jaros
PReS-ABS-1028	IDIOPATHIC ARTHRITIS	(Poland)
	CONCOMITANT MRI FEATURES OF SACROILIITIS	
	INCREASE SPECIFICITY FOR DIAGNOSIS OF JUVENILE	
PReS-ABS-1346	SPONDYLOARTHRITIS.	Lennart Jans (Belgium)
PReS-ABS-1153	THERMAL POINT OF CARE DIAGNOSTIC TOOL FOR MEASUREMENT OF JOINT INFLAMMATION	Lovro Lamot (Croatia)

	MONITORING DISEASE SEVERITY IN EXPERIMENTAL	
	ARTHRITIS BY IMAGING OF PHAGOCYTE MIGRATION IN	
PReS-ABS-1403	VIVO	Sandra Gran (Germany)
	SUBLINICAL SYNOVITIS ON US IN PATIENTS WITH NEW-	
	ONSET JUVENILE IDIOPATHIC ARTHRITIS DOES NOT	
	PREDICT EARLY APPEARANCE OF CLINICAL DISEASE	
PReS-ABS-1268	EXCEPT FOR THE ANKLE JOINT	Stefano Lanni (Italy)
	REDUCED JOINT COUNT FOR ULTRASOUND ASSESSMENT	Valentina Litta Modignani
PReS-ABS-1620	IN JUVENILE IDIOPATHIC ARTHRITIS	(Italy)
	MUSCULOSKELETAL ULTRASOUND USEFULNESS IN THE	
	DIAGNOSIS AND TREATMENT IN PEDIATRIC	Vitor André Teixeira
PReS-ABS-1027	RHEUMATOLOGY	(Portugal)
	TRANSIENT PERIOSTEAL HYPEROSTOSIS WITH	
PReS-ABS-1422	DYSPROTEINEMIA (GOLDBLOOM SYNDROME): TWO	Riccardo Papa
	CASES REPORT	

# Around JIA - Chairs: Nico Wulffraat & Joost Swart

	DOWN'S ARTHROPATHY - CLINICAL AND RADIOLOGICAL	
PReS-ABS-1198	FEATURES OF ARTHRITIS IN CHILDREN WITH TRISOMY 21	Charlene Foley (Ireland)
	THE EVALUATION OF EFFICACY OF ADALIMUMAB IN	
	JUVENILE IDIOPATHIC ARTHRITIS-ASSOCIATED UVEITIS	Ekaterina Gaidar (Russian
PReS-ABS-1462	AND CHRONIC ANTERIOR UVEITIS.	Federation)
	RETROSPECTIVE STUDY EVALUATING TREATMENT	
	DECISION AND OUTCOME OF NON-JUVENILE IDIOPATHIC	
PReS-ABS-1214	ARTHRITIS (JIA)-ASSOCIATED CHILDHOOD UVEITIS	Elham Sardar (France)
	HUMORAL AND CELLULAR RESPONSES TO VARICELLA	
	VACCINATION OF PATIENTS WITH PEDIATRIC RHEUMATIC	
	DISEASES – PRELIMINARY RESULTS OF A VACCINATION	
PReS-ABS-1574	STUDY	I Grein (Netherlands)
	SHARE UPDATE – 508 FAMILIES VIEW ON STANDARD OF	
	CARE FOR CHILDREN WITH JUVENILE IDIOPATHIC	Ingrid Herta Rotstein Grein
PReS-ABS-1464	ARTHRITIS IN EUROPE AND ISRAEL	(Netherlands)
	INTERNET PROGRAM FOR PHYSICAL ACTIVITY AND	
	EXERCISE-CAPACITY IN CHILDREN WITH JUVENILE	
	IDIOPATHIC ARTHRITIS; A MULTICENTER RANDOMIZED	
PReS-ABS-1467	CONTROLLED TRIAL.	Joyce Bos (Netherlands)
	ANTI-DFS70 ANTIBODIES: NEW BIOMARKERS FOR UVEITIS	Lorenza Maria Argolini
PReS-ABS-1555	IN JUVENILE IDIOPATIC ARTHRITIS?	(Italy)
	USE OF THE XBOX KINECT VIRTUAL GAMING SYSTEM TO	
	IMPROVE UPPER EXTREMITY FUNCTIONS AND ACTIVITY	
	PERFORMANCE IN PATIENTS WITH WITH JUVENILE	
PReS-ABS-1594	IDIOPATHIC ARTHRITIS	Nilay Arman (Turkey)
	JIA-UVEITIS IN THE SHARED-CARE CONTEXT: IS POOR	Rebecca Angela James
PReS-ABS-1442	DOCUMENTATION PUTTING PATIENTS AT RISK?	(United Kingdom)

# Predicting JIA outcome - Chairs: Johannes Roth & Alessandro Consolaro

	INFLUENCE OF FOKI VITAMIN D RECEPTOR (VDR) AND	
	TNFA-308 TUMOR NECROSIS FACTOR GENE	Dragana S Lazarevic
PReS-ABS-1407	POLYMORPHISM ON LONG TERM DISEASE OUTCOME IN	(Serbia)

	JUVENILE IDIOPATHIC ARTHRITIS (JIA) TOWARDS STRATIFIED MEDICINE IN JUVENILE	Emily Robinson (United
PReS-ABS-1300		
	IDIOPATHIC ARTHRITIS ATTITUDES AND APPLICATIONS OF THE MYELOID	Kingdom)
	RELATED PROTEIN (MRP8/14) IN THE MANAGEMENT OF	Deter Dele (United
	JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE CENTRE	Peter Bale (United
PReS-ABS-1112	EXPERIENCE CD4+ T CELL DNA METHYLATION IN OLIGOARTICULAR	Kingdom)
	JUVENILE IDIOPATHIC ARTHRITIS STRATIFIED BY AGE AT	Raul Antonio Chavez
	DIAGNOSIS, AND PERSISTENT OR EXTENDED DISEASE	
PReS-ABS-1284		Valencia (Australia)
PReS-ABS-1580	ORAL HEALTH AND ANTI-CITRULLINATED PEPTIDE	Sriharsha Grevich (United
	ANTIBODIES (ACPA) IN JUVENILE IDIOPATHIC ARTHRITIS	States)
	THE INFLUENCE OF EARLY ACHIEVEMENT OF CLINICALLY	Chambonia Lagana Mainan
	INACTIVE DISEASE ON LONG-TERM DISABILITY	Stephanie Joanna Weiner
PReS-ABS-1349		Shoop (United Kingdom)
	EARLY PREDICTION FOR SUSTAINED LONG-TERM	
	EFFICACY OF THE 1ST BIOLOGIC AGENT IN	
	POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS; A	
PReS-ABS-1321	MULTI-CENTER STUDY IN JAPAN.	Tomohiro Kubota (Japan)
	BASELINE PREDICTORS OF LONG-TERM REMISSION IN A	Veronika Gjertsen Rypdal
PReS-ABS-1413	NORDIC JUVENILE IDIOPATHIC ARTHRITIS COHORT	(Norway)
	NEXT GENERATION SEQUENCING REVEALS COMPLEMENT DEFICIENCIES ARE THE MOST FREQUENT CAUSES OF	
PReS-ABS-1570	MONOGENIC LUPUS IN CHILDREN	Alexandre Belot (France)
	INTERSTITIAL LUNG DISEASE WITH TMEM173	
	MUTATIONS IS ASSOCIATED WITH A STRONG IFN-	
PReS-ABS-1359	STIMULATED PROTEIN INDUCTION IN SITU.	Cecile Picard (France)
	EFFICACY OF RITUXIMAB IN CHILDHOOD-ONSET	
	SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE	Ekaterina Kuchinskaya
PReS-ABS-1018	STUDY OF 16 PATIENTS	(Russian Federation)
11103 AD3 1010		Erika Van Nieuwenhove
PReS-ABS-1385	IKAROS DEFICIENCY IN EARLY ONSET LUPUS	(Belgium)
11103 AB3 1303	FATIGUE IN JSLE: ANALYSIS OF PREVALENCE AND	(
	ASSOCIATIONS IN A LARGE, NATIONAL COHORT OF	Hanna Lythgoe (United
PReS-ABS-1122	PATIENTS	Kingdom)
	COMPARISON ANALYSIS OF NON-BACTERIAL AND	Olga Kopchak (Russian
PReS-ABS-1308	TUBERCULOUS OSTEOMYELITIS.	Federation)
1 NE3-AD3-1300	URINARY BIOMARKER PRODUCTION IN JUVENILE LUPUS	Rachael Deborah Wright
PReS-ABS-1163	NEPHRITIS – ROLE OF THE PODOCYTES	(United Kingdom)
	CAN INDIVIDUAL EXPOSURE TO AIR POLLUTION TRIGGER	
PReS-ABS-1210	DISEASE ACTIVITY AND AGGRAVATE NEPHRITIS IN	
	CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS	Andressa Guariento
	PATIENTS?	Ferreira Alves (Brazil)
	BEHÇET'S DISEASE IN CHILDREN: EASTERN	Hafize Emine Sönmez
PReS-ABS-1287	MEDITERRANEAN EXPERIENCE	(Turkey)
	IS HARADA SCORE A USEFUL TOOL IN MEXICAN	Fernando Garcia-Rodrigue
PReS-ABS-1520	CHILDREN WITH KAWASAKI DISEASE?	(Mexico)